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Mammalian genes are highly heterogeneous with respect to their nucleotide composition, but the functional
consequences of this heterogeneity are not clear. In the previous studies, weak positive or negative correlations have
been found between the silent-site guanine and cytosine (GC) content and expression of mammalian genes. However,
previous studies disregarded differences in the genomic context of genes, which could potentially obscure any
correlation between GC content and expression. In the present work, we directly compared the expression of GC-rich
and GC-poor genes placed in the context of identical promoters and UTR sequences. We performed transient and
stable transfections of mammalian cells with GC-rich and GC-poor versions of Hsp70, green fluorescent protein, and IL2
genes. The GC-rich genes were expressed several-fold to over a 100-fold more efficiently than their GC-poor
counterparts. This effect was not due to different translation rates of GC-rich and GC-poor mRNA. On the contrary, the
efficient expression of GC-rich genes resulted from their increased steady-state mRNA levels. mRNA degradation rates
were not correlated with GC content, suggesting that efficient transcription or mRNA processing is responsible for the
high expression of GC-rich genes. We conclude that silent-site GC content correlates with gene expression efficiency in
mammalian cells.
Citation: Kudla G, Lipinski L, Caffin F, Helwak A, Zylicz M (2006) High guanine and cytosine content increases mRNA levels in mammalian cells. PLoS Biol 4(6): e180. DOI: 10.
1371/journal.pbio.0040180
Introduction
In the standard genetic code, all U$C and almost all A$G
substitutions in the third positions of codons are synon-
ymous. Consequently, every protein sequence can be encoded
by a large number of different nucleotide sequences, ranging
from nearly 0%–100% G and C nucleotides in the third
codon positions. In most organisms, the variation in guanine
and cytosine (GC) content among genes is modest; for
example, 90% of Saccharomyces cerevisiae genes have GC3
contents (proportion of G and C in the third positions of
codons) between 30% and 50%. The diversity of codon usage
in humans and other mammals is larger than in most other
species. The GC3 content of human genes ranges from 20%
to more than 95% (Figure 1). It is believed that this broad
variation in nucleotide usage is caused by the large-scale
variation of nucleotide composition (isochore structure) of
mammalian genomes. Genes located in GC-rich isochores
tend to be more GC-rich than genes located in the GC-poor
isochores [1,2], and the GC content of pseudogenes increases
following their insertion into GC-rich isochores [3]. This
suggests that the same evolutionary force is responsible for
the isochore structure of mammalian genomes and for the
codon usage of genes. However, the precise mechanism that
underlies the formation of isochores and the diversiﬁcation
of nucleotide usage in genes is not yet clear.
The question of selection on synonymous sites in mamma-
lian genes is widely debated (recently reviewed in [4]). In the
early studies, silent (synonymous) sites in mammals were
assumed to evolve neutrally, and it is still believed that a large
majority of silent mutations are neutral. The strongest
support for this view comes from an analysis of evolutionary
rates at silent sites. Synonymous sites are believed to evolve as
fast as the genomic average [5], ancient repeats [6], and
introns [7,8], although some authors report lower silent
evolutionary rates [9,10]. Silent substitution rates are also
uncorrelated with gene expression breadth and tissue-
speciﬁcity [11]. These results suggest that most synonymous
mutations are not opposed by purifying selection in
mammals. Furthermore, it is known from studies of bacteria,
yeast, and ﬂies that selection intensity on silent sites is
correlated with gene expression level, leading to increased
codon bias in highly expressed genes in these organisms [12–
16]. The lack of clear correlation between codon usage and
expression level or breadth in mammals (reviewed in [17])
further supports the neutral evolution of silent sites.
And yet, some observations lend support to the existence of
selection on silent sites in mammals. The frequency distribu-
tions of silent polymorphisms in mammalian genes are
compatible with nucleotide usage being determined by
selection (or biased gene conversion), but not by regional
mutation bias [18,19]. The average GC content is higher at
silent sites than in neighboring non-coding regions [20],
suggesting that high GC content in coding regions could
confer some selective advantage. The patterns of tissue-
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PLoS BIOLOGYspeciﬁcity in the codon usage of human genes [21,22],
although weak, could indicate translational selection on
silent sites. Local codon bias in human genes depends on
the position relative to splice sites [23,24], and, as demon-
strated in the CFTR gene, a surprisingly high proportion of
synonymous mutations results in exon skipping and protein
inactivation [25]. Many human diseases are caused by
synonymous mutations resulting in aberrant splicing [4].
Finally, synonymous substitution rates vary within mamma-
lian genes, and a case of unusually high sequence conserva-
tion at synonymous sites in the BRCA1 gene has been
attributed to selection [26]. Most of these arguments are
indirect, highlighting the need for experimental studies of
mammalian codon usage evolution.
Selection on silent sites requires the existence of functional
differences between synonymous genes. Although several
cases of such differences have been demonstrated in
mammals, they are mostly related to differential splicing of
synonymous gene variants. On the other hand, little is known
about the effects of nucleotide usage at silent sites on gene
expression efﬁciency. Several recent studies reported weak
positive or negative correlations between the GC content and
expression levels of mammalian genes [17,27–32]. All these
works relied on estimations of expression levels of endoge-
nous genes using microarrays or analyses of EST or SAGE
databases. These are powerful approaches in terms of the
amounts of experimental data analyzed. However, since gene
expression depends on many factors other than codon
usage—such as transcriptional regulation or mRNA UTRs—
these studies provide only very indirect insight into the
possible effects of codon usage on expression. To eliminate
all factors other than nucleotide usage itself, one needs to
compare directly the expression of GC-rich and adenine and
thymine-rich GC-poor genes, placed in the context of
identical promoters and UTR sequences. Here we use this
direct experimental approach to study the effects of GC
content on the expression of Hsp70, green ﬂuorescent
protein (GFP), and IL2 genes in mammalian cells.
Results
In the ﬁrst set of experiments, we compared the expression
of genes from the mammalian Hsp70 family. We have recently
shown that despite the very high similarity of their encoded
proteins, mammalian Hsp70-family genes display large differ-
ences in their nucleotide usage [33,34]. We used the human
HSPA1A gene (GC3 ¼ 92%, encoding heat-inducible Hsp70)
and the human HSPA8 gene (GC3 ¼ 46%, encoding
constitutive Hsc70). The coding regions of both genes have
similar lengths (1,920 and 1,926 nucleotides) and their
encoded proteins share 85% identity. To enable a direct
comparison of HSPA1A and HSPA8 expression, independent
of their genomic context, we cloned their cDNA coding
regions into pcDNA3.1 mammalian expression vectors. The
59- and 39- UTRs were comprised of the pcDNA3.1 vector
sequence, and they were identical in both vectors. HA tags
were used to enable easy comparison of protein expression
levels, and the ﬁrst three codons in HSPA8 were replaced by
HSPA1A codons to avoid differences in the Kozak translation
initiation sequence.
We transfected HeLa cells using equal amounts of
pcDNA3-Hsp70-HA or pcDNA3-Hsc70-HA vectors. Follow-
ing 24 h of incubation at 37 8C, the cells were harvested and
the Hsp70-HA and Hsc70-HA proteins were quantiﬁed by
Western blotting using an anti-HA antibody. The Hsp70-HA
protein, encoded by the GC-rich gene, was at least ten times
more abundant than Hsc70-HA (Figure 2A). The difference
was consistently observed over a 3-fold range of plasmid
concentrations (Figure S1A) and was apparent as soon as 3 h
post-transfection, when the Hsp70-HA protein ﬁrst appeared
(unpublished data). Identical results were obtained using
293T cells (Figure S1B). Since HSPA1A is a heat-inducible
gene, we tested whether high GC content facilitates its
expression at high temperatures. We found that the ratio of
Hsp70-HA to Hsc70-HA protein levels did not change with
temperature in the range from 28 8Ct o4 28C (unpublished
data), suggesting that HSPA1A expression is enhanced
independently of temperature.
Among the 641 codons in the HSPA1A gene, 77% are the
preferred human codons, i.e., those that are most frequently
used in human genes. In comparison, only 39% of the codons
in HSPA8 are preferred human codons. We therefore
hypothesized that the difference in Hsp70-HA and Hsc70-
HA protein abundance in cells might be due to different
translation rates of these proteins. To explore this possibility,
we performed in vitro translation experiments. Equal
amounts of Hsp70 and Hsc70 mRNA (1.5 lg each) were used
for translation in rabbit reticulocyte lysates in the presence of
35S-methionine. The only detectable protein products in the
translation reactions corresponded to complete Hsp70 and
Hsc70 polypeptides. The Hsp70 and Hsc70 proteins both
appeared between 12 and 14 min after the reaction started
(Figure 2B). There was no detectible difference in the rates of
Hsp70 and Hsc70 translation.
If the translation rates of Hsp70 and Hsc70 are similar,
then their different cellular protein levels could arise from a
difference in mRNA abundance. To test this possibility, we
quantiﬁed Hsp70-HA and Hsc70-HA mRNA using real-time
RT-PCR, by amplifying a fragment of the 39 UTR identical in
both mRNAs. 24 h after the transfection of HeLa cells, the
amount of Hsp70-HA mRNA was over 10-fold higher than the
Figure 1. Distribution of Human Genes with Respect to Their GC3
Contents, and GC3 Contents of Genes Used in This Study
Data adapted from the Codon Usage Database [71].
DOI: 10.1371/journal.pbio.0040180.g001
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High GC Content Increases mRNA Levelsamount of Hsc70-HA mRNA (Figure 2C). No Hsp70-HA or
Hsc70-HA mRNA was detected in untransfected HeLa cells
(Figure 2C). To control for possible differences in trans-
fection efﬁciencies, we quantiﬁed the mRNA of the neomycin
resistance (neo) gene expressed from both plasmids. The neo
mRNA levels were identical in the Hsp70 and Hsc70-trans-
fected cells, suggesting that both plasmids were transfected
with equal efﬁciencies (Figure 2D). The equal loading of total
mRNA in all samples was also conﬁrmed using a cellular
housekeeping gene, GAPDH (Figure 2E). Thus, the difference
in the Hsp70 and Hsc70 cellular mRNA levels results from
their different transcription efﬁciency or mRNA stability.
Similar results were obtained using 293T cells (Figure S1C–E).
Taken together, these results lead to the hypothesis that GC
content may strongly affect the expression efﬁciency of
HSPA1A and HSPA8 genes.
To test the possibility that high GC content might increase
gene expression in mammalian cells, we used plasmids
encoding either a modiﬁed GC-poor jellyﬁsh GFP gene
(GC3 ¼ 35%) or a GC-rich version of the gene, EGFP (GC3
¼ 96%). The Kozak sequences of both genes, the encoded
protein sequences, and the plasmid sequences around the
genes were identical. 24 h following transfection of HeLa
cells, the overall EGFP ﬂuorescence was 20–30 times higher
than GFP ﬂuorescence (Figure 3A–C). The same result was
seen in 293T cells and at times ranging from 6–36 h post-
transfection (unpublished data), in agreement with previous
reports [35]. We next investigated the amounts of GFP or
EGFP mRNA produced in transiently transfected HeLa cells.
mRNA was quantiﬁed by real-time RT-PCR, using a fragment
of the 39 UTR that was identical in both genes. As shown in
Figure 3D, the steady-state level of EGFP mRNA was 20–50
times higher than that of GFP mRNA in HeLa cells. As a
control, neo mRNA levels were similar for both plasmids,
suggesting that the transfection efﬁciencies of pGFP-N2 and
pEGFP-N2 plasmids did not differ (Figure 3E). The same
results were obtained in 293T cells (unpublished data). Since
the ratio of EGFP to GFP mRNA levels was similar to the ratio
of their protein levels, it is reasonable to conclude that mRNA
level and not translation rate is responsible for the efﬁcient
EGFP protein synthesis in human cells.
It is usually believed that selection on silent sites does not
signiﬁcantly affect codon usage in mammals. Thus, even if a
gene becomes GC-poor and inefﬁciently expressed, perhaps
because of its location in a GC-poor isochore, selective forces
are not strong enough to improve the codon usage of that
gene. It follows that many mammalian genes may have codon
usage patterns that do not support their efﬁcient expression.
We analyzed human genes used in biotechnology or pharma-
ceutical industry. Several of them have GC3 contents below
60%, the median GC3 content of human genes (Table S1). To
test whether the expression of these genes could be
modulated by changing their GC content, we used synthetic
nucleotide usage variants of the IL2 gene.
The IL2 protein is produced by T cells in response to
antigenic stimulation. It performs a variety of immunosti-
Figure 2. Expression of Hsp70 (GC3 ¼ 92%) and Hsc70 (GC3 ¼ 46%)
(A) Three independent clones of pcDNA3-Hsp70-HA (GC3¼92%) and six clones of pcDNA3-Hsc70-HA (GC3¼46%) were used to transfect HeLa cells. 24
h following transfection the cells were harvested and the Hsc70-HA or Hsp70-HA protein levels were analyzed by Western blotting using an anti-HA
antibody. An anti-GAPDH antibody was used as loading control. (B) Equal amounts of Hsp70 and Hsc70 mRNA were used as templates for in vitro
translation in rabbit reticulocyte lysates in the presence of
35S-Methionine. The reaction was initiated by the addition of reticulocyte lysate to the
translation mix and samples were removed in 2-min intervals into SDS sample buffer. The reaction products were analyzed by SDS-PAGE and
autoradiography. (C–E) HeLa cells were transfected with equal amounts of pcDNA3-Hsp70-HA or pcDNA3-Hsc70-HA plasmids. After 24 h, total cellular
RNA was isolated and analyzed by qRT-PCR. The graphs represent Hsp or Hsc70 (C), neo (D), and GAPDH (E) mRNA amounts. Hsp70, cells transfected
with pcDNA3-Hsp70-HA; Hsc70, cells transfected with pcDNA3-Hsc70-HA; control, untransfected cells. The mRNA amounts were normalized to the
amounts in the Hsp70-transfected cells. The error bars represent standard deviations from three to four independent transfections.
DOI: 10.1371/journal.pbio.0040180.g002
PLoS Biology | www.plosbiology.org June 2006 | Volume 4 | Issue 6 | e180 0935
High GC Content Increases mRNA Levelsmulatory functions, including the induction of proliferation
of T and B lymphocytes [36]. Recombinant IL2 (as Proleukin)
is used in therapy of metastatic renal cell carcinoma and
metastatic melanoma, and cancer gene therapy trials using
IL2 cDNA are ongoing [37–39]. An important factor in gene
therapy and biotechnology is the efﬁciency of therapeutic
gene expression. Since the original human IL2 gene has a low
GC content (GC3 ¼ 41%) that could potentially hamper its
expression, we attempted to enhance IL2 expression using a
synthetic version of the gene, eIL2 (enhanced IL2, GC3 ¼
100%). To provide additional controls for the relationship
between GC content and expression, we used wIL2 (weakened
IL2, GC3 ¼ 7%), and a fusion gene containing half of the IL2
gene and half of the eIL2 gene (IL2-eIL2, GC3¼70%). All four
IL2 constructs encode exactly the same protein sequence, and
they were cloned into the pcDNA3.1 vector using the same
restriction sites.
The production of IL2 protein from the four constructs
was measured by ELISA in cell culture supernatants. As
expected, IL2 protein synthesis increased with increasing GC
content of the genes (Figure 4A and 4C). In HeLa cells, the
eIL2 gene was expressed 5-fold stronger, and the IL2-eIL2
hybrid 3-fold stronger than the original IL2 gene. The
expression of the wIL2 gene was so weak that the protein
was not detectable in the HeLa cell culture media. In Saos-2
cells, protein synthesis of eIL2 and IL2-eIL2 was 13-fold and 3-
fold stronger, respectively, than of wild-type IL2, while
protein synthesis of wIL2 was ﬁve times lower than wild-type.
Real-time RT-PCR experiments demonstrated a very similar
positive correlation between GC content and mRNA levels,
both in HeLa and Saos-2 cells (Figure 4B and 4D). These
experiments support the hypothesis that the nucleotide usage
of mammalian genes can be modiﬁed to increase their mRNA
levels.
We next wanted to check whether GC content would affect
the expression of genes integrated into mammalian chromo-
somes, as opposed to genes expressed from plasmids. Stable
integration of transgenes eliminates many problems poten-
tially associated with transient transfection, such as unequal
plasmid concentration or purity and different transfection
efﬁciency. We ﬁrst used the MCF-7 human breast cancer cell
line to integrate the various GFP and IL2 constructs into
random genomic locations. As a negative control, we stably
transfected MCF-7 cells with an empty pcDNA3.1 plasmid.
Clones were selected using G418, and three to ﬁve clones of
each type were used for measurements of mRNA and protein
levels. As shown in Figure 5A, all the clones containing the
GC-rich EGFP gene produced 10-fold to 100-fold more
ﬂuorescence than the clones expressing the GC-poor GFP
gene, indicating increased EGFP protein levels. A similar
result was obtained when comparing GFP and EGFP mRNA
levels (Figure 5B). The IL2 mRNA and protein levels also
correlated very strongly with the GC contents of stably
integrated IL2 gene variants (Figure 5C and 5D). In this case,
the variation in expression levels spanned several orders of
magnitude, and considerable variation existed even among
clones expressing the same gene (see e.g., Figure 5D, IL2
gene). However, none of the clones transfected with the GC-
poorest wIL2 gene produced signiﬁcant amounts of IL2
mRNA or protein (Figure 5C and 5D).
Random genomic integration of transgenes often results in
a large variation of expression between clones, due to
differences in integration sites or transgene copy numbers.
In order to avoid this variation, we next used the Flp-In T-
Rex-293 cell line to integrate single copies of the GFP or IL2
variants into a speciﬁc genomic location. The Flp-In T-Rex-
293 cells also contain a Tet-ON inducible expression system.
To eliminate possible artifacts caused by constitutive trans-
Figure 3. Expression of EGFP (GC3 ¼ 96%) and GFP(GC3 ¼ 35%) in Transiently Transfected Cells
(A–C) HeLa cells were transfected with pGFP-N2 or pEGFP-N2 plasmids. 24 h following transfection, cells were trypsinized and washed, and GFP and
EGFP protein levels were analyzed by flow cytometry. (A) Control cells. (B) Cells transfected with pGFP-N2. (C) Cells transfected with pEGFP-N2. The
horizontal axes represent green fluorescence. (D and E) Expression of GFP and EGFP mRNA. HeLa cells were transfected with pGFP-N2 or pEGFP-N2
plasmids. After 24 h, total cellular RNA was isolated and analyzed by qRT-PCR. The graphs represent GFP or EGFP (D) and neo (E) mRNA amounts.
Control, untransfected cells. The results are representative of three experiments.
DOI: 10.1371/journal.pbio.0040180.g003
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High GC Content Increases mRNA Levelsgene expression during the selection process, clones were
selected in the absence of tetracycline. We then measured the
transgene expression following tetracycline addition. After
12–24 h following induction, EGFP mRNA and protein levels
were around ten times higher than GFP levels (Figure 6A and
6B). eIL2-transfected cells produced 5- to 10-fold more
transgenic mRNA and protein than IL2-transfected cells
(Figure 6C and 6D). In contrast, the wIL2 protein and mRNA
levels barely exceeded background measurements in the
parental Flp-In T-Rex-293 cell line. Similar results were also
obtained with TM3-FRT cells, with site-directed integration
and constitutive, CMV promoter-driven expression of the
GFP and IL2 transgenes (unpublished data). As expected, the
variation between clones was much lower in the cells with
site-directed transgene integration than in the cells with
random integration sites (Figures 5 and 6 and unpublished
data).
To test whether slow degradation or efﬁcient synthesis
caused the increased steady-state levels of GC-rich mRNA, we
performed mRNA stability studies using an inhibitor of
transcription, actinomycin D. HeLa cells were transfected
with Hsp70, Hsc70, or with the GC-rich or GC-poor versions
of GFP or IL2 genes. 20 h following transfection, the cells
were treated with actinomycin D for 0–7 h, and mRNA was
quantiﬁed by real-time RT-PCR. Two cellular mRNA species:
GAPDH (stable) and c-myc (unstable) were also quantiﬁed to
control the proper transcription inhibition by actinomycin
D. As expected, the measured half-life of GAPDH mRNA was
around 7 h, while the half-life of c-myc mRNA was below 1 h
(Figure 7). The stabilities of GC-rich and GC-poor mRNA
species were similar in all cases (Figure 7). The mRNA half-
lives were: Hsp70, 2.9 h; Hsc70, 3.8 h; EGFP, 4.8 h; GFP, 3.3 h;
eIL2, 4.5; IL2, 3.9 h. These slight differences in mRNA
stabilities lifetimes are unlikely to account for the large
difference in steady-state levels of GC-rich and GC-poor
mRNA species. This result suggests that enhanced mRNA
transcription or co-transcriptional processing accounts for
the increased expression of GC-rich genes in mammalian
cells.
Discussion
We have shown that the efﬁciency of mRNA production
from GFP, IL2, and Hsp70-family genes in mammalian cells
correlates with the silent-site GC content of these genes.
Although the origin of GC content variability in human genes
attracts much interest, the effect of GC content on gene
expression in mammalian cells has not been previously
addressed in a direct experimental way. However, previous
Figure 5. Expression of GFP and IL2 Variants in Stably Transfected MCF-7
Cells
MCF-7 cells were stably transfected with expression plasmids containing
GFP (GC3 ¼35%), EGFP (GC3 ¼96%), wIL2 (GC3¼7%), IL2 (GC3¼41%),
IL2-eIL2 (GC3 ¼ 70%), eIL2 (GC3 ¼ 100%), or with an empty pcDNA3.1
plasmid. The expression plasmids contained CMV promoters and were
integrated in random genomic locations. Protein and mRNA was
quantified in three to five individual clones for each transgene. (A) Flow
cytometry measurements of GFP and EGFP protein levels. (B) Real-time
RT-PCR measurements of GFP and EGFP mRNA levels. (C) ELISA
measurements of the IL2 protein levels. (D) real-time RT-PCR measure-
ments of IL2 mRNA levels. GFP and IL2 mRNA levels were normalized to
GAPDH mRNA. The controls represent pcDNA3.1-transfected cells. The
vertical axis in each graph represents arbitrary units.
DOI: 10.1371/journal.pbio.0040180.g005
Figure 4. Expression of Human Interleukin 2 (IL2) Variants in Transiently
Transfected Cells
(A and B) HeLa cells were transfected with plasmids encoding the IL2
variants. 24 h following transfection, cell culture media were used for
protein quantification by ELISA, and adhering cells for mRNA measure-
ments by real-time RT-PCR. (A) ELISA measurement of IL2 protein levels
using serial dilutions of culture media. Black squares, enhanced IL2 (eIL2,
GC3¼100%); white squares, IL2-eIL2 hybrid (IL2-eIL2, GC3¼70%); black
triangles, wild-type IL2 (IL2, GC3 ¼ 41%); white triangles, weakened IL2
(wIL2, GC3 ¼ 7%). The result is representative of three experiments. (B)
Real-time RT-PCR measurement of IL2 mRNA. IL2 mRNA levels were
normalized to GAPDH mRNA. Error bars represent standard deviations
from two to four independent transfections using different plasmid
preparations. (C and D) same as (A and B) using Saos-2 cells.
DOI: 10.1371/journal.pbio.0040180.g004
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relationship between nucleotide usage and expression. In
mammalian expression systems, the codon optimization
strategy consists in increasing the proportion of preferred
(i.e., most frequently used) mammalian codons in target
genes. Since all of the preferred mammalian codons have G
or C nucleotides in the third positions, codon-optimized
genes are necessarily GC-rich. We reevaluated the results of
published codon optimization experiments by analyzing the
effects of GC content on gene expression (Table 1). All these
results support the higher expression of GC-rich genes as
compared to adenine and thymine-rich genes. The ratio of
GC-rich to adenine and thymine-rich gene expression levels
varies from 2.5-fold to over 1,000-fold (Table 1). This large
variation is understandable, considering the different degrees
of codon usage modiﬁcation and different methods for
quantifying gene expression. It has often been assumed that
the increased expression of codon-optimized genes was
caused by a translational mechanism [40–42], although this
possibility has not been thoroughly tested experimentally
(but see [43]). Here we suggest that most of the observed
codon optimization effects in mammalian cells may be
attributed to expression changes at the mRNA level. For
example, optimization of GFP has been assumed to enhance
its translation rate [40]; instead, we have shown that codon
optimization increases GFP mRNA levels.
In some of the previous studies, increased mRNA levels
contributed to the enhanced protein levels of codon-
optimized (GC-rich) genes (Table 1, [44–46]). A codon-
optimized version of HIV-1 gag (GC3 ¼ 98%), was expressed
in H1299 cells 100-fold more efﬁciently than wild-type gag
(GC3 ¼ 38%), both at mRNA and protein levels [44]. Unlike
the wild-type gene, codon-optimized gag was expressed
independently of the cis-acting mRNA regulatory elements,
and did not require the RNA-interacting protein Rev for
efﬁcient expression [44,47]. Similar effects of codon opti-
mization were also shown for the HIV-1 gag-pol gene [45] and
for HIV-1 vif and vpu genes [46]. The latter study demon-
strated that codon optimization enhanced nuclear export,
but not the transcriptional efﬁciency of vif and vpu mRNA.
Furthermore, the GC-poor HPV-16 L1 (GC3 ¼ 26%) and L2
genes (GC3 ¼ 16%) as well as BPV-1 L1 and L2 genes (GC3 ¼
36%) have been shown to contain potent cis-acting mRNA-
down-regulating elements in their open reading frames
(ORF) [48,49]. The HPV-16 L2 elements operate in an
orientation-dependent manner, and their effect is partially
explained by cytoplasmic RNA destabilization [48]. Most
interestingly, the effects of L1 and L2 inhibitory elements
could be overcome by T7 polymerase-driven cytoplasmic
transcription in a vaccinia virus-based system, suggesting that
most of the mRNA down-regulation takes place at the stage of
transcription or nuclear export [48,50]. A recent study of the
mammalian GC-poor L1 retrotransposon expression shows
Figure 7. Stability of GC-Rich and GC-Poor mRNA in Mammalian Cells
HeLa cells were transfected with the indicated plasmids and after 20 h they were treated with 10 lg/mL actinomycin D. At the indicated times, mRNA
was isolated and quantified by real-time RT-PCR. The GAPDH and c-myc mRNA levels represent the means of their levels in cells transfected with GC-rich
and GC-poor genes. In each graph, little circles represent GAPDH and crosses, c-myc. (A) black circles, Hsp70; white circles, Hsc70. (B) black squares,
EGFP; white squares, GFP. (C) Black triangles, eIL2; white triangles, IL2. The data is representative of two independent experiments.
DOI: 10.1371/journal.pbio.0040180.g007
Figure 6. Expression of GFP and IL2 Variants in Stably Transfected Flp-In
T-Rex-293 Cells
The GFP or IL2 variants under the control of tetracycline-inducible CMV
promoters were integrated into the single FRT site of Flp-In T-Rex-293
cells. Protein and mRNA was quantified in three to five individual clones
for each transgene. (A) Flow cytometry measurements of GFP and EGFP
protein levels 24 h post-induction. (B) Real-time RT-PCR measurements of
GFP and EGFP mRNA levels 12 h post-induction. (C) ELISA measurements
of the IL2 protein levels 24 h post-induction. (D) Real-time RT-PCR
measurements of IL2 mRNA levels 24 h post-induction. GFP and IL2
mRNA levels were normalized to GAPDH mRNA. The controls represent
CAT- transfected cells (A) or the parental Flp-In T-Rex-293 cell line (B and
D). The vertical axis in each graph represents arbitrary units.
DOI: 10.1371/journal.pbio.0040180.g006
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High GC Content Increases mRNA Levelsthat its mRNA is down-regulated at posttranscriptional or
transcriptional levels depending on the ORF sense or
antisense orientation [51,52]. Increasing the proportion of
TpA dinucleotides in the human DRD2 gene lowered its
mRNA stability, while increasing the proportion of CpG
dinucleotides increased the stability [53]. Finally, two codon
optimization studies failed to detect differences in the levels
of GC-rich and adenine and uracil (AU)-rich mRNAs [43,54].
In one of these works, different probes were used to compare
GC-rich and AU-rich mRNA abundance without correction
for hybridization efﬁciency, weakening the conclusions [43].
Taken all together, results obtained in most prior studies are
compatible with our hypothesis that high GC content
enhances mRNA levels in human cells.
The increased mRNA levels of GC-rich genes detected in
this and previous studies can result from two mechanisms,
not mutually exclusive: increased mRNA synthesis or
decreased mRNA degradation. Interestingly, both RNA syn-
thesis and degradation could potentially be affected by GC
content in coding regions. It is well documented that AU-rich
elements located in the 39 UTRs can act to destabilize mRNA
[55–57]. cis-acting RNA-destabilizing elements have also been
detected in the coding regions of several genes [50,58–61], but
they remain poorly characterized. Most of the mRNAs that
harbor coding region instability elements happen to be GC-
poor (i.e., factor VIII, IL2, c-myc, c-fos, HPV, and HIV-1
mRNAs), but it is not known whether a general correlation
exists between cellular mRNA lifetime and GC3 content. On
the other hand, low GC content might also be associated with
low transcription or RNA processing efﬁciency. The efﬁcient
expression of GC-poor genes in a T7 polymerase-driven
transcription system in mammalian cells supports this type of
mechanism. Low RNA-DNA duplex stability [62] and runs of
uridines [63] have been implicated in abnormal pausing and
arrest of mammalian RNA polymerase II, and U-rich motifs as
well as the conserved AAUAAA signal play a role in normal
transcription termination [64]. High GC content could also
facilitate DNA transitions from B to A or Z conformation
[65,66], thereby affecting transcription factor binding or RNA
polymerase processivity [67,68]. The possible effects of DNA
conformational transitions on nucleotide usage evolution
have been previously described [69].
To distinguish between the effects of GC content on mRNA
synthesis versus mRNA degradation in this study, we
performed actinomycin D chase experiments. We demon-
strated that GC content does not signiﬁcantly affect the
cellular mRNA lifetimes of GFP, IL2, and Hsp70 genes.
Further, we have shown that destruction of the single AU-
rich element-like sequence element in the GFP coding region
does not enhance GFP expression (unpublished data),
suggesting that AU-rich element-mediated RNA destabiliza-
tion is not responsible for the low GFP expression. Taken
together, these results suggest that the high expression of GC-
rich genes results primarily from the efﬁcient production of
polyadenylated mRNA, through efﬁcient transcription or co-
transcriptional processing. The observation that codon usage
optimization can enhance gene expression in homologous
systems (as in the case of the IL2 optimization) may have
important implications for biotechnology and medicine.
It is important to note that we have neither proved nor
















GFP 32 (67) 293 5–22 ND — [40]
BPV1 L1 36 (72) Cos-1 over 1,000 1–3 Increased translation rate [43]
HIV env ND
b 293T 41– over 200 , 1 — [54]
Rat Thy-1 ND
b 293 100 ND — [54]
HIV env ND
b 293T 10–50 ND Increased immunogenicity [42]
LLO91–99, CSP281–290
c 0 (100) 3T3, Cos7 up to 100 ND Increased immunogenicity [72]
HIV gag-pol 35 (78)
d 293T, HeLa 10 10 Rev-independent expression,
CRM1-independent mRNA export
[45]




b 293 25 ND — [41]
DRD2 57(90) CHO ND 7.5 Increased mRNA lifetime [53]
L1 retrotransposon 41(96) HeLa, 3T3 þþþ
e þþþ
e 200-fold higher retrotransposition
activity
[51]
EPO 27(95) 293T, CHO 2.5
f ND — [73]
HIV vpu, HIV vif 37(58)
g 293T, HeLa þþþ
e þþþ
e Enhanced stability and nuclear
export of mRNA
[46]
aGC3 content in the GC-poor (GC-rich) genes used in the study.
bThe use of GC-poor and GC-rich genes is inferred from indirect data in the papers.
cEpitopes from Listeria monocytogenes and Plasmodium yoelii genes, fused to the luciferase gene.
dGC3 content in the gag gene.
eHighly significant difference, but numerical value not given.
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mammalian genes. While the differences in expression levels
between GC-rich and GC-poor genes are very important,
single AT$GC substitutions may only cause minor changes in
expression. The selective coefﬁcients associated with such
minor changes may be too small to affect the evolutionary
outcomes in small mammalian populations. It might be
tempting to hypothesize that the paucity of GC-poor (GC3 ,
25%) genes in mammalian genomes is related to their very
low expression efﬁciency. Ultimately, population genetical
studies will be required to address these issues. Our results
suggest that selection on silent sites is in principle possible in
mammals, and that it is more likely to act through transcrip-
tional than translational mechanisms.
Interestingly, the correlation between GC content and
mRNA levels has not been detected in most genome-wide
microarray and SAGE studies [17,28,70]. This might suggest
that the correlation reported here concerns only a limited
number of genes. However, given the wealth of experimental
data supporting the increased expression of GC-rich genes
(both here and in previous studies on codon optimization),
we believe that this phenomenon may be general. Since the
GC content of a gene changes slowly, the effects of GC
content on expression could be easily compensated by
relatively faster changes in promoter, UTR, or intron
sequences. Such compensation would decrease the correla-
tion observed in genome-wide studies, which do not control
for the genomic context of each gene. A comparative analysis
of mammalian and lower vertebrate genes could resolve
whether or not GC content changes within genes are
associated with compensating changes in their regulatory
sequences.
Materials and Methods
Plasmids. pcDNA3.1(þ) and pcDNA3.1( ) were from Invitrogen
(Invitrogen, Carlsbad, California, United States). These plasmids
contain a strong constitutive CMV promoter, a BGH polyadenylation
signal, and a neomycin resistance gene for G418-based selection of
mammalian cells.
pcDNA3-Hsp70-HA: the HSPA1A (gi: 188487) coding region was
ampliﬁed by PCR using the Hsp70-HA-U and Hsp70-HA-L primers
(see Table S2). This appended an HA tag to the Hsp70 ORF. The PCR
product was digested with EcoRV and XhoI and inserted into the
EcoRV and XhoI sites of the pcDNA3.1 vector (Invitrogen), under the
control of the CMV promoter.
pcDNA3-Hsc70-HA: the HSPA8 (gi: 32466) coding region was
ampliﬁed by PCR from HeLa cDNA using the Hsc70-HA-U and
Hsc70-HA-L primers (Table S2). This replaced the ﬁrst three Hsc70
amino acids with Hsp70 amino acids, improved the Hsc70 Kozak
sequence, and appended an HA tag to the Hsc70 ORF. The PCR
product was digested with EcoRV and XhoI and inserted into the
EcoRV and XhoI sites of the pcDNA3.1 vector (Invitrogen).
pEGFP-N2 was from Clontech (Clontech, Palo Alto, California,
United States).
pGFP-N2 was constructed by ﬁrst introducing the R80Q mutation
into the GFP sequence in the pS65T-C1 vector (Clontech) using the
GFP-R80Q-U and GFP-R80Q-L primers, then by introducing the
F64L mutation, using the GFP-F64L-U and GFP-F64L-L primers, and
then by amplifying the coding region of the modiﬁed GFP using the
BamHI-59-GFP and GFP-39-NotI primers (Table S2). The PCR
product was digested with BamHI and NotI and then inserted into
the BamHI and NotI sites of the pEGFP-N2 vector. The resulting
pGFP-N2 vector encoded a GFP with an identical amino acid
sequence and Kozak sequence as pEGFP-N2 (see Dataset S1).
pcDNA3-IL2 was constructed by extracting the IL2 cDNA from
pWPXL-IL2 (kind gift from D. Kowalczyk) using BamHI and EcoRI
and insertion into the BamHI, EcoRI sites of pcDNA3.1 (þ).
pcDNA3-eIL2 and pcDNA3-wIL2 were constructed by introducing
the synthetic eIL2 or wIL2 genes (ordered from Geneart, Regensburg,
Germany) into the HindIII, EcoRI sites of pcDNA3.1 (þ). The
sequences of eIL2 and wIL2 can be found online in the Dataset S1.
pcDNA3-IL2-eIL2 was constructed from pcDNA-IL2 by replacing a
fragment of the IL2 gene by a fragment of the eIL2 gene, PCR-
ampliﬁed from pcDNA-eIL2 using the eIL2-1152-U and eIL2-1480-L
primers (Table S2) and digested with XbaI.
pcDNA5/FRT-IL2, pcDNA5/FRT-wIL2, and pcDNA5/FRT-eIL2
were constructed by extracting the IL2, wIL2, and eIL2 coding
regions, respectively, from pcDNA3-IL2, pcDNA3-wIL2, and
pcDNA3-eIL2 using HindIII and NotI and inserting them into the
HindIII, NotI sites of pcDNA5/FRT/TO (Invitrogen).
pcDNA5/FRT/CAT was from Invitrogen.
pcDNA5/FRT-GFP and pcDNA5/FRT-EGFP were generated by
subcloning the BamHI, NotI fragments from pEGFP-N2 or pGFP-
N2 into the pcDNA5/FRT/TO vector digested with BamHI and NotI.
Following cloning, the coding regions of all plasmids were
sequenced.
Cell culture. Adherent HeLa cells and 293T cells were cultured at
37 8C in a humidiﬁed atmosphere containing 5% CO2, in Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM, Sigma D5523, Sigma, St. Louis,
Missouri, United States) with 10% heat-inactivated Fetal Bovine
Serum (FBS, Sigma F7524) and the antibiotic/antimycotic mixture
(Sigma). Saos-2 cells (ATCC) were cultured in McCoy’s medium with
15% non-inactivated FBS and the antibiotic/antimycotic mixture.
MCF-7 cells (ATCC) were grown in RPMI-1640 (Sigma) containing
10% FBS. For stable transfection of MCF-7 cells, linearized plasmids
were transfected using Lipofectamine 2000 (Invitrogen), and clones
were selected using 750 lg/mL neomycin (G418 Sigma). The Flp-In T-
Rex-293 cell line (Invitrogen) and Flp-In TM3 cells (mouse Leydig
cells, L. Lipinski, unpublished data) were cultured in DMEM with 4.5
g/mL glucose, 10% FBS, 100 lg/mL zeocin. 15 lg/mL blasticidin was
additionally used for the Flp-In T-Rex-293 cell line. Following the
transfection of Flp-In cells, stable transfectants were selected using
100 lg/mL hygromycin B instead of zeocin. Generation of clonal cell
lines was performed according to manufacturer’s instructions (Flp-In
T-Rex Core Kit, Instruction manual, Invitrogen). Total cellular DNA
of individual Flp-In T-Rex-293-derived and Flp-In TM3-derived
clones was analyzed by qPCR to conﬁrm the presence of a single
transgene copy in each clone. GFP and IL2 expression in Flp-In T-
Rex-293 cells was induced by adding 1 lg/ml tetracycline for 24 h
before harvesting.
For transient transfection of HeLa cells, 5.5 3 10
4 cells per well
were seeded in a 24-well plate (Corning, New York, United States).
For each well, 0.3 lg plasmid DNA and 1 lL Lipofectamine 2000
(Invitrogen) were used according to the manufacturer’s instructions.
Following 24 h of incubation, 50%–80% transfection efﬁciency and
. 95% cell viability was routinely achieved, as detected by
ﬂuorescence microscopy, immunoﬂuorescence microscopy, and ﬂow
cytometry. For transfection of 293T cells, 8 3 10
4 cells per well were
used in a 24-well plate. For each well, 0.4 lg pure plasmid DNA was
mixed with 25 lL DMEM without FBS, and 0.8 lL1m g / m L
polyethyleneimine (PEI, Polysciences Incorporated, Warrington,
Pennsylvania, United States) in H2O was added to this mixture,
incubated 10 min at room temperature and the solution was added
onto the cells. The transfection efﬁciency and cell viability was similar
as for HeLa cells. For transfection of Saos-2 cells, 1.6 3 10
5 cells per
well were seeded in a 12-well plate. For each well, 0.8 lg DNA was
mixed with 50 lL DMEM, 1.6 lL of 1 mg/mL PEI was added, incubated
10 min, and spread on the cells. Transfection efﬁciency was 20%. For
mRNA quantiﬁcation, all transfections were scaled up to 6-well
plates.
SDS-PAGE and Western blotting. Cells were washed once with ice-
cold PBS and lysed directly in the wells in 70 lL13 SDS sample
buffer, boiled for 5 min and amounts corresponding to about 5 lg
total protein per lane were loaded on 10% poliacrylamide gels. A
prestained protein ladder (PAGE-Ruler, Fermentas, Burlington,
Ontario, Canada) was routinely used. Following electrophoresis,
proteins were transferred onto a nitrocellulose membrane (Pall)
using a Bio-Rad blotting system (Bio-Rad, Hercules, California,
United States). The following antibodies were used for detection:
rabbit anti-HA, sc-805 (Santa Cruz Biotechnology), 1:2000; rabbit
anti-GAPDH, sc-25778 (Santa Cruz Biotechnology), 1:6000; goat anti-
rabbit IgG-HRP conjugated, 401393 (Calbiochem, San Diego, Cal-
ifornia, United States), 1:6000. The membranes were soaked in the
chemiluminescence reagent immediately before exposure to a Kodak
BioMax ﬁlm.
Flow cytometry. Cells were trypsinized, washed with medium
containing 10% FBS, resuspended in PBS with 5% DMSO, and stored
at 70 8C. The ﬂow cytometry analysis was performed using BD FACS
Calibur. Forward scatter and side scatter measurements were used to
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was used to detect the GFP or EGFP ﬂuorescence. For ﬂuorescence
quantiﬁcation, the arithmetic mean of all events corresponding to
living cells was used.
IL2 ELISA. 24 h following transfection, cell culture media were
gathered and centrifuged 1 min at 14,000 rpm. Supernatants were
diluted to the appropriate concentration with PBS þ 10% heat-
inactivated FBS, and IL2 concentrations were measured using the
OptEIA human IL2 ELISA set (BD Biosciences, Palo Alto, California,
United States) according to the manufacturer’s instructions.
In vitro transcription and translation. Capped Hsp70 and Hsc70
mRNA was produced in vitro using the T7 Cap Scribe kit (Roche,
Basel, Switzerland) according to the manufacturer’s instructions. The
mRNA was analyzed by 1% agarose gel electrophoresis to conﬁrm the
absence of degradation. The in vitro translations were performed at
28 8C using the Reticulocyte Translation Kit Type II (Roche) and
35S-
labeled Methionine (Amersham Biosciences, Little Chalfont, United
Kingdom). The reactions contained 1–2 lg Hsp70 or Hsc70 mRNA, 2
lL translation reaction mix without methionine, 50 mM potassium
acetate, 1.25 mM magnesium acetate, 2 lL
35S-Met (10 mCi/mL), and
10 lL rabbit reticulocyte lysate, in a total reaction volume of 25 lL.
The reactions were started by the addition of rabbit reticulocyte
lysate, and stopped after the desired time by addition of SDS sample
buffer, followed by SDS-PAGE and autoradiography.
mRNA quantiﬁcation. Total cellular RNA was puriﬁed using the
NucleoSpin kit (Macherey Nagel, Germany) according to the
manufacturer’s instructions. The NucleoSpin puriﬁcation procedure
comprises on-column DNA digestion using DNAse I. On several
occasions, we veriﬁed the absence of contaminating plasmid DNA in
our RNA preparations by omitting the reverse transcriptase in the RT
reactions and then performing the real-time PCR. We never observed
any signiﬁcant contamination with this puriﬁcation method. RNA
concentration was measured spectrophotometrically, and approx-
imately 1.5 lg of total RNA was used in each cDNA synthesis reaction.
cDNA synthesis was performed using the RevertAid kit (Fermentas)
with (dT)18 primers. Real-time PCR cDNA quantiﬁcation was
performed using Light-Cycler (Roche) with Sybr Green II (Sigma).
The primer sequences are shown in the Table S2. The equal
transfection efﬁciency in transient transfection experiments was
controlled using the neomycin resistance gene (neo), present in all
our experimental constructs. The neo gene cDNA from the pEGFP-
N2 and pGFP-N2 plasmids was ampliﬁed using the neo(GFP) primers,
and the neo gene cDNA from the pcDNA3-Hsp70-HA, pcDNA3-
Hsc70-HA, and all the pcDNA3-IL2 plasmids—using the neo(pcDNA)
primers. The IL2 and GFP variants expressed in the Flp-In cells were
quantiﬁed using the pcDNA5-UTR-U and pcDNA5-UTR-L primers.
For RNA stability assays, cells were treated with 10 lg/mL actino-
mycin D (Sigma) for 0–7 h before RNA isolation. mRNA half-lives
were determined by ﬁtting exponential decay curves to experimental
data points.
Supporting Information
Dataset S1. Sequences of the IL2 and GFP Gene Variants
Found at DOI: 10.1371/journal.pbio0040180.sd001 (3 KB DOC).
Figure S1. Expression of Hsp70 (GC3¼92%) and Hsc70 (GC3¼46%)
in HeLa and 293T Cells
(A) HeLa cells were transfected using 0.1, 0.2, or 0.3 lg of pcDNA3-
Hsp70-HA or pcDNA3-Hsc70-HA plasmids and the protein expres-
sion levels 24 h after transfection were analyzed by Western blotting.
(B) Same as (A), using 293T cells. (C–E) 293T cells were transfected
with equal amounts of pcDNA3-Hsp70-HA or pcDNA3-Hsc70-HA
plasmids. After 24 h, total cellular RNA was isolated and analyzed by
qRT-PCR. The graphs represent Hsp/c70 (C), neo (D), and GAPDH (E)
mRNA amounts. Hsp70, cells transfected with pcDNA3-Hsp70-HA;
Hsc70 cells, transfected with pcDNA3-Hsc70-HA; control, untrans-
fected cells. The mRNA amounts were normalized to the amounts in
the Hsp70-transfected cells. The error bars represent standard
deviations from 3–4 independent transfections.
Found at DOI: 10.1371/journal.pbio.0040180.sg001 (71 KB PDF).
Table S1. Human GC-Poor Genes (GC3 , 60%) Used in Therapy
Found at DOI: 10.1371/journal.pbio.0040180.st001 (35 KB DOC).
Table S2. Primers Used for Cloning and Real-Time RT-PCR
Found at DOI: 10.1371/journal.pbio.0040180.st002 (44 KB DOC).
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